Opendata, web and dolomites

V-LAP SIGNED

A revolutionary direct, daily heart monitoring platform for long-term tailored treatment of Heart Disease patients.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 V-LAP project word cloud

Explore the words cloud of the V-LAP project. It provides you a very rough idea of what is the project "V-LAP" about.

code    left    meet    pressure    weeks    synchronize    chronic    lap    implantable    nhs    monitor    leg    glucose    body    decreasing    30    detecting    98    excess    minimally    mortality    threatening    life    12    disruptive    pump    ac    65    blood    hospital    28    prescription    decompensate    causes    miniaturized    red    tiredness    measured    indicator    battery    adhf    portfolio    sent    quality    symptoms    transition    external    coupling    least    medications    data    patient    earliest    unable    ing    catheter    clothes    procedure    free    total    vectorious    heart    device    healthcare    clinicians    covered       flow    adjust    worldwide    edema    acute    expenditure    collected    diabetes    hf    people    organs    hospitalization    dyspnea    filling    patents    inductive    swelling    predict    ventricular    takes    sudden    completely    aged    yellow    min    powered    worsening    back    website    mobile    global    color    promptly    worn    day    invasive    provider    lv    fluids    green    patients    ineffective    hemodynamic    belt    invasively    events    daily    levels   

Project "V-LAP" data sheet

The following table provides information about the project.

Coordinator
VECTORIOUS MEDICAL TECHNOLOGIES LTD 

Organization address
address: RAUL WALLENBERG 24
city: TEL AVIV JAFFA
postcode: n.a.
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website https://vectoriousmedtech.com/
 Total cost 2˙621˙146 €
 EC max contribution 1˙834˙802 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-04-01   to  2020-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    VECTORIOUS MEDICAL TECHNOLOGIES LTD IL (TEL AVIV JAFFA) coordinator 1˙834˙802.00

Map

 Project objective

Heart failure (HF) is a chronic condition affecting 1 in 5 people aged over 65 worldwide: heart is unable to pump enough blood flow to meet the body needs. The resulting excess of fluids in body and organs causes dyspnea, edema, leg swelling and tiredness, decreasing patients’ life quality. The sudden worsening of symptoms is called Acute Decompensate Heart Failure: a life-threatening condition with 30% mortality within 12 weeks. HF costs are high: 28 B€/year to EU NHS, 2% of total healthcare expenditure, the major part due to hospitalization. There is today a global call to increase awareness in HF, whose management is still highly ineffective. The transition from HF to the acute condition takes weeks but its earliest indicator, an increase in left ventricular filling pressure (LV), can only be measured invasively, in a hospital. Vectorious’ disruptive device is a miniaturized, battery-free, implantable hemodynamic monitor capable of detecting the rise in LV during patient’s daily life. The implantable, completely covered by Vectorious’ patents portfolio, is deployed through a minimally invasive, catheter-based procedure. A belt-like external device is worn by the patient over the clothes 3 min/day: via inductive AC coupling, the implantable is powered so pressure data can be collected and sent back to the external unit which synchronize with the patient’s mobile device and with a dedicated website for the healthcare provider. A green/yellow/red color code widely known among HF patients allows them to promptly adjust their medications, according with their clinicians’ prescription. V-LAP will be able to predict at least 98% ADHF events, HF management will become as simple as manage glucose levels in diabetes.

 Deliverables

List of deliverables.
Project webpage Websites, patent fillings, videos etc. 2019-07-22 17:27:08

Take a look to the deliverables list in detail:  detailed list of V-LAP deliverables.

 Publications

year authors and title journal last update
List of publications.
2019 Leor Perl, Elina Soifer, Jozef Bartunek, Dedi Erdheim, Friedrich Köhler, William T. Abraham, David Meerkin
A Novel Wireless Left Atrial Pressure Monitoring System for Patients with Heart Failure, First Ex-Vivo and Animal Experience
published pages: , ISSN: 1937-5387, DOI: 10.1007/s12265-018-9856-3
Journal of Cardiovascular Translational Research ~13K Publications so far 2019-07-19

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "V-LAP" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "V-LAP" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MCBD (2019)

MCBD (MULTI-CORE BIOPSY DEVICE) INNOVATIVE BIOPSY TECHNOLOGY FOR THE NEW ERA OF TARGETED MEDICINE

Read More  

In-Heal (2019)

Standardised administration device for raw medical herbs

Read More  

CAARESYS (2019)

CAARESYS: vehicle passenger monitoring system based on contactless low emission radio frequency radar.

Read More